Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Haemophilus influenzae type b Polysaccharide Conjugated to Tetanus Protein Carrier (Hib PRP-TT)
- Target
- Hib PRP-TT
- Molecular classification
- Polysaccharide-protein conjugate, Vaccine antigen
01
Overview
Haemophilus influenzae type b (Hib) polysaccharide conjugated to tetanus protein carrier is the active component in Hib conjugate vaccines. The vaccine induces an immune response by presenting the bacterial polysaccharide in a form that can be recognized efficiently by the immune system. Conjugation with tetanus toxoid converts the normally T-cell independent PRP antigen into a T-cell dependent form, enabling robust antibody production even in infants and young children who would otherwise respond poorly to plain polysaccharides. Protective immunity correlates with anti-PRP antibody concentrations.
- Other names
- Hib conjugate vaccineHiberixActHIBPRP-TT
02
Mechanism of action
Induces anti-PRP antibody production by converting a T-cell independent antigen (PRP) into a T-cell dependent antigen through conjugation to tetanus toxoid.
03
Biological functions
Induction of adaptive immune responseAntibody productionImmunological memory formationPrevention of bacterial infection
04
Disease associations
Prevention of Haemophilus influenzae type b infectionsPrevention of meningitisPrevention of pneumoniaPrevention of epiglottitisPrevention of sepsis
05
Safety considerations
Local injection site reactions (pain, swelling)FeverRare allergic reactions
06
Interacting drugs
None (component of vaccines, not a drug itself)
07
Biomarkers
Anti-PRP antibody concentration (>0.15 mcg/mL is considered protective)
Beyond the preview
Go deeper on Haemophilus influenzae type b Polysaccharide Conjugated to Tetanus Protein Carrier (Hib PRP-TT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haemophilus influenzae type b Polysaccharide Conjugated to Tetanus Protein Carrier (Hib PRP-TT).